Detection of HER2-positive Circulating Tumor Cells Using the LiquidBiopsy System in Breast Cancer

Chen, Weirong; Zhang, Juncheng; Huang, Lei; Chen, Lin; Zhou, Yanling; Tang, Dongjiang; Xie, Yingming; Wang, Hong; Huang, Chuoji

doi:10.1016/j.clbc.2018.10.009

Cited by 36 publications

(25 citation statements)

References 28 publications

(32 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Secondly, we found out—using ISH, the most reliable assay for HER2 status—that nearly 10% of MBC patients with HER2-negative tumor exhibit HER2 amp CTC. The presence of such HER2-positive CTC (detected by ISH or immunocytology) has been reported by several observational studies [9,13–19]. In our study, both the absolute number of HER2 amp CTC and the HER2 amp /HER2-negative CTC ratio were low, suggesting that these HER2 amp CTC account for a minority of the tumor burden and that HER2 amp subclones do not expand significantly during therapy in MBC patients.…”

Section: Discussionsupporting

confidence: 70%

Actionability of HER2-amplified circulating tumor cells in HER2-negative metastatic breast cancer: the CirCe T-DM1 trial

et al. 2019

View full text Add to dashboard Cite

BackgroundIn this prospective phase 2 trial, we assessed the efficacy of trastuzumab-emtansine (T-DM1) in HER2-negative metastatic breast cancer (MBC) patients with HER2-positive CTC.MethodsMain inclusion criteria for screening were as follows: women with HER2-negative MBC treated with ≥ 2 prior lines of chemotherapy and measurable disease. CTC with a HER2/CEP17 ratio of ≥ 2.2 by fluorescent in situ hybridization (CellSearch) were considered to be HER2-amplified (HER2amp). Patients with ≥ 1 HER2amp CTC were eligible for the treatment phase (T-DM1 monotherapy). The primary endpoint was the overall response rate.ResultsIn 154 screened patients, ≥ 1 and ≥ 5 CTC/7.5 ml of blood were detected in N = 118 (78.7%) and N = 86 (57.3%) patients, respectively. ≥1 HER2amp CTC was found in 14 patients (9.1% of patients with ≥ 1 CTC/7.5 ml). Among 11 patients treated with T-DM1, one achieved a confirmed partial response. Four patients had a stable disease as best response. Median PFS was 4.8 months while median OS was 9.5 months.ConclusionsCTC with HER2 amplification can be detected in a limited subset of HER2-negative MBC patients. Treatment with T-DM1 achieved a partial response in only one patient.Trial registrationNCT01975142, Registered 03 November 2013

show abstract

Section: Discussionsupporting

confidence: 70%

Actionability of HER2-amplified circulating tumor cells in HER2-negative metastatic breast cancer: the CirCe T-DM1 trial

et al. 2019

View full text Add to dashboard Cite

show abstract

“…( 25 ) Detection of HER2+ CTCs in patients with breast cancer can identify candidates for targeted therapy. ( 26 ) Although CTCs are highly promising as a form of liquid biopsy, there are technical challenges to be overcome before there can be widespread use of CTCs. Most importantly, CTCs have an extremely rare frequency in the circulation, and the number of CTCs tends to be proportional to tumor volume, which makes their detection in early‐stage disease challenging.…”

Section: Overview Of Ctc Biology and Clinical Implicationsmentioning

confidence: 99%

Detection of Circulating Tumor Cells and Their Implications as a Biomarker for Diagnosis, Prognostication, and Therapeutic Monitoring in Hepatocellular Carcinoma

et al. 2021

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is among the leading causes of worldwide cancer‐related morbidity and mortality. Poor prognosis of HCC is attributed primarily to tumor presentation at an advanced stage when there is no effective treatment to achieve the long term survival of patients. Currently available tests such as alpha‐fetoprotein have limited accuracy as a diagnostic or prognostic biomarker for HCC. Liver biopsy provides tissue that can reveal tumor biology but it is not used routinely due to its invasiveness and risk of tumor seeding, especially in early‐stage patients. Liver biopsy is also limited in revealing comprehensive tumor biology due to intratumoral heterogeneity. There is a clear need for new biomarkers to improve HCC detection, prognostication, prediction of treatment response, and disease monitoring with treatment. Liquid biopsy could be an effective method of early detection and management of HCC. Circulating tumor cells (CTCs) are cancer cells in circulation derived from the original tumor or metastatic foci, and their measurement by liquid biopsy represents a great potential in facilitating the implementation of precision medicine in patients with HCC. CTCs can be detected by a simple peripheral blood draw and potentially show global features of tumor characteristics. Various CTC detection platforms using immunoaffinity and biophysical properties have been developed to identify and capture CTCs with high efficiency. Quantitative abundance of CTCs, as well as biological characteristics and genomic heterogeneity among the CTCs, can predict disease prognosis and response to therapy in patients with HCC. This review article will discuss the currently available technologies for CTC detection and isolation, their utility in the clinical management of HCC patients, their limitations, and future directions of research.

show abstract

“…There are indication that HER2 gene copy number can be assessed in serum of peripheral blood as a predictive marker for qualification or monitoring of targeted treatment with trastuzumab in breast cancer patients. Moreover, there are studies on HER2 -positive free-circulating tumor cells which indicate the possibility of using this diagnostic and monitoring tool in breast cancer patients [ 27 , 28 ].…”

Section: Discussionmentioning

confidence: 99%

HER2 gene assessment in liquid biopsy of gastric and esophagogastric junction cancer patients qualified for surgery

et al. 2020

View full text Add to dashboard Cite

Background Amplification of HER2 gene (ERBB2) and overexpression of HER2 protein on cancer cells are found in 10–26% of gastric cancer (GC) and esophagogastric junction cancer (EGJC). Gene copy number variation (CNV) could be detected in these patients in liquid biopsy and in cancer cells. Methods We analysed HER2 gene CNV used qPCR method in 87 sera collected from GC and EGJC patients before surgical treatment and in 40 sera obtained from healthy donors. HER2 gene CNV was also assessed in formalin-fixed paraffin-embedded (FFPE) tumor tissue. Furthermore, we assessed the number of HER2 gene copies and HER2 expression in cancer cells using the fluorescent in situ hybridization method (FISH) and immunohistochemistry (IHC). Results We found that the HER2 gene copy number in liquid biopsy was higher in GC and EGJC patients compared to healthy people (p = 0.01). Moreover, EGJC patients had higher number of HER2 gene copies than healthy donors (p = 0.0016). HER2 CNV examination could distinguish healthy individuals and patients with gastric or esophagogastric junction cancers with sensitivity and specificity of 58% and 98% (AUC = 0.707, 95% CI 0.593–0.821, p = 0.004). We found that patients with a high copy number of the HER2 gene in the tumor tissue assessed by qPCR (but not by FISH) have significantly more often a high number of HER2 gene copies in liquid biopsy (p = 0.04). Conclusions We suggested that HER2 testing in liquid biopsy could be used as an auxiliary method to analysis of HER2 status in tumor tissue in gastric or esophagogastric junction cancers.

show abstract

Detection of HER2-positive Circulating Tumor Cells Using the LiquidBiopsy System in Breast Cancer

Cited by 36 publications

References 28 publications

Actionability of HER2-amplified circulating tumor cells in HER2-negative metastatic breast cancer: the CirCe T-DM1 trial

Actionability of HER2-amplified circulating tumor cells in HER2-negative metastatic breast cancer: the CirCe T-DM1 trial

Detection of Circulating Tumor Cells and Their Implications as a Biomarker for Diagnosis, Prognostication, and Therapeutic Monitoring in Hepatocellular Carcinoma

HER2 gene assessment in liquid biopsy of gastric and esophagogastric junction cancer patients qualified for surgery

Contact Info

Product

Resources

About